Présentation de l'entreprise
Evaxion A/S operates as a clinical-stage biotechnology enterprise focused on the development of artificial intelligence-powered immunology vaccines, specifically targeting advanced melanoma and solid tumors through its pipeline assets EVX-01 and EVX-03. The company functions within the healthcare sector and the biotechnology industry, where high-risk, long-duration research and development activities are the norm for advancing novel therapeutic candidates. As of the latest reporting period, the firm employs 46 individuals and maintains a total market capitalization of $33.86M, while generating $7.53M in annual revenue. These financial metrics indicate that Evaxion is a small-cap entity with a limited revenue base relative to its valuation, suggesting the market prices the stock primarily on the potential future value of its clinical pipeline rather than current operational cash flows. The disparity between its modest revenue generation and its market valuation highlights the speculative nature of early-stage biotech investments where equity value is detached from current profitability.
Santé financière
The company reported a revenue of $7.53M over the trailing twelve months, yet it recorded a net income of $-7,707,000 and an EBITDA of $-8,873,000, revealing a significant gap between top-line generation and bottom-line profitability driven by substantial operating expenses. The free cash flow stands at $-4,449,750, which indicates that the company is burning cash to fund its research and development efforts rather than generating liquidity for shareholder returns or debt servicing. Evaxion presents a unique margin profile with a gross margin of 100.0%, reflecting the absence of cost of goods sold in its current operational model, contrasted sharply by an operating margin of -122.7% and a profit margin of -102.4% that underscore heavy overhead costs relative to sales. The balance sheet shows a cash position of $23.23M against total debt of $7.50M, supported by a debt-to-equity ratio of 44.04, suggesting the firm carries leverage but holds sufficient liquid assets to cover its obligations. Liquidity is robust with a current ratio of 5.85, indicating that the company possesses more than five times the current assets necessary to meet its short-term liabilities. Finally, the return on equity is -100.2% and the return on assets is -28.2%, metrics that reveal management is currently destroying shareholder value due to significant losses, a typical characteristic for pre-revenue or clinical-stage biotechnology firms.
Évaluation de la valorisation
Valuation metrics for Evaxion are complex due to its lack of consistent earnings, as the trailing twelve-month P/E ratio is N/A while the forward P/E is calculated at 101.50, implying that the market expects earnings to turn positive or stabilize significantly in the future to justify the current price. The price-to-book ratio stands at 1.99, indicating that the market values the company at nearly double its tangible book value, a premium often associated with intangible assets like intellectual property and clinical trial data. Alternative valuation measures further illustrate the speculative stance, with a price-to-sales ratio of 4.50 and an EV/EBITDA of -189.04, which suggests the stock is priced based on future revenue potential rather than current operational performance or cash flow generation. Regarding trading ranges, the 52-week high is $12.15 and the 52-week low is $1.20, meaning the current price sits in a wide volatility band far below the recent peak. The beta value of 0.20 indicates that the stock's price volatility is significantly lower than the broader market, moving with a dampened sensitivity to general market fluctuations despite its high valuation multiples.
Growth & Income
Evaxion's financial growth profile is characterized by a revenue growth rate of -100.0% and an earnings growth rate of N/A, reflecting the transition from prior revenue streams to a new clinical-stage business model where earnings are not yet realized. Since the company does not pay dividends, with a dividend yield of N/A and a payout ratio of 0.0%, it reinvests all available capital back into its research and development programs rather than distributing income to shareholders. The absence of a dividend policy is a strategic necessity for a firm with negative free cash flow and no current profits, ensuring that limited resources are directed toward advancing its vaccine pipeline. Overall, the growth and income profile of Evaxion is purely speculative, relying entirely on the successful progression of its clinical trials to eventually generate positive returns, with no current income stream to support shareholder wealth creation.